Navigation Links
Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
Date:7/24/2008

REHOVOT, Israel and JERSEY CITY, New Jersey, July 24 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq: ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced today that it has successfully completed the acquisition of Parkway Clinical Laboratories Inc. ("Parkway"), a privately-held company owning a CLIA-certified lab located in Bensalem, Pennsylvania, for an aggregate purchase price of $2,900,000, consisting of $1,900,000 in cash and $1,000,000 of Rosetta's ordinary shares. An additional $300,000 will be payable upon the achievement of certain milestones. The lab owned by Parkway is an CLIA-certified clinical reference laboratory with an expected $2.7M in revenues and break-even operating income in 2008.

The acquisition is expected to allow Rosetta Genomics to expedite development and validation of its microRNA-based diagnostic tests both in the U.S. and worldwide. In addition, ownership of the CLIA-certified lab will allow Rosetta Genomics to control the commercialization of its diagnostics, including marketing, sales, and reimbursement strategy. As previously disclosed, the first three of Rosetta Genomics' microRNA-based tests expected to enter development and validation at Parkway's facilities this year:

- Differentiating squamous from non-squamous non-small cell

lung cancer- This test is designed to differentiate squamous from

non-squamous non-small cell lung cancer (NSCLC) using a single

microRNA. The ability of physicians to accurately differentiate

squamous from non-squamous NSCLC is an important treatment guide.

Certain angiogenesis inhibitors for non-squamous NSCLC include a

black-box warning about substantially higher rates of severe or fatal

hemorrhage among patients with squamous NSCLC histology compared with

non-squamous NSCLC. In addition, several other targeted drugs for NSCLC

currently under development may require this sensitive differentiation.

- Differentiating mesothelioma from adenocarcinoma - This

differentiation is critical for optimal therapy, but is often difficult

to perform. Currently, there is no objective, standardized test to aid

pathologists in differentiating between the many possible tumors in

the lung and pleura. Based on several microRNA biomarkers, this test

is designed to separate mesothelioma from adenocarcinoma tumors

including lung adenocarcinoma and metastases to the lung or to the

pleura.

- Identifying origin of metastases (CUP) - In 3%-5% of all new

cancer patients, clinicians cannot identify the origin of a patients'

tumor. This information is crucial for determining treatment type. As

demonstrated in a paper published by Rosetta Genomics and

collaborators in the April issue of Nature Biotechnology, Rosetta

Genomics has developed a panel of microRNA biomarkers potentially able

to identify approximately thirty cancer types. This test is designed

to assist clinicians to accurately identify the origin of tumors.

In addition, the company expects the following three tests to enter development during 2009-2010: response prediction to ovarian cancer treatment, predicting risk of gastric cancer recurrence, and differentiation of small cell from non-small cell lung cancer.

About MicroRNA

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the completion of the acquisition of Parkway by Rosetta and the expected impact of the acquisition will have on the commercialization of Rosetta's microRNA-based diagnostics, Parkway's expected revenues and operating income for 2008, the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease and the expected timing of the development and commercialization of diagnostic tests using our microRNA technology constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; Rosetta's ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007, as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contact:

Media

Rachel Spielman

T: +1-212-583-2714

E: media@rosettagenomics.com

Investors

Ron Kamienchick

T: +1-646-509-1893

E: investors@rosettagenomics.com


'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference
2. Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
3. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
4. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
5. /C O R R E C T I O N -- Rosetta Genomics Ltd/
6. Rosetta Genomics Reports First Quarter 2008 Financial Results
7. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
8. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
9. Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference
10. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology
11. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
(Date:11/30/2016)...  The Allen Institute for Cell Science has ... available collection of gene edited, fluorescently tagged human ... structures with unprecedented clarity. Distributed through the Coriell ... a crucial first step toward visualizing the dynamic ... human cells healthy and what goes wrong in ...
(Date:11/30/2016)... , Nov. 30, 2016  Tempus, a technology ... care, and Penn,s Abramson Cancer Center have partnered ... positive response to immunotherapy treatment based on next ... As part of a research collaboration, Tempus will ... melanoma cancer patient data to Penn. Utilizing next-generation ...
(Date:11/30/2016)... , 30. November 2016   ... hat heute die Unterzeichnung einer Reihe von ... zufolge wird Evotec AG Screeningleistungen für Mercks ... bereitstellen. Der Zugriff auf diese Bibliotheken in ... eröffnet einen schnelleren Weg zur Ermittlung und ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
Breaking Biology News(10 mins):